Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Sanofi)
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Menactra is a quadrivalent meningococcal conjugate vaccine (MCV4) developed by Sanofi Pasteur. It is composed of capsular polysaccharides from *Neisseria meningitidis* serogroups A, C, Y, and W-135, each individually conjugated to a diphtheria toxoid protein carrier. The vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by these specific serogroups in individuals aged 9 months through 55 years. By conjugating the polysaccharides to a protein carrier, the vaccine induces a T-cell dependent immune response, leading to the production of high-affinity bactericidal antibodies and the establishment of immunological memory. It was the first quadrivalent meningococcal conjugate vaccine licensed in the United States (2005).
- Brand names
- Menactra
- Other names
- MenACWY-DTMCV4MCV-4MCV 4Quadrivalent meningococcal conjugate vaccineMeningococcal A, C, Y, W-135 diphtheria toxoid conjugate vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Sanofi).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Sanofi).